Senolytics — OutliveHub

Promising Cellular — Research on cellular-level aging mechanisms Other PubMed

Popular Senolytic Drugs Failed to Work in Rigorous Independent Testing

Drugs once thought to slow aging didn't work in independent tests—be cautious about anti-aging claims until proven by multiple labs.

Researchers from multiple labs independently tested two widely-publicized senolytic drugs (a GLS1 inhibitor and anti-PD-1 antibody) and found they did not reduce senescent cells or improve aging in mice—contradicting earlier claims. This highlights a serious …

EMBO reports

60 Promising

Disputed Cellular — Research on cellular-level aging mechanisms In Vitro bioRxiv

A genetic tweak that quiets inflammation in aging cells

Scientists found a way to quiet the inflammatory signals from aging cells without stopping their aging arrest—a potential new approach to reduce age-related inflammation.

Researchers found that a mutated histone protein (H2A.Z R80C) can suppress the inflammatory signals that senescent cells emit—a hallmark of aging—without stopping the cell-cycle arrest that defines senescence. This opens a new way to potentially …

biorxiv (preprint)

24 Weak

Preliminary Pharmacological — Drugs and compounds that may slow or reverse aging. Rapamycin, metformin, NAD+ … Other PubMed

Senolytic treatment induces oligodendrocyte dysfunction and demyelination in the corpus callosum.

Aging is a primary risk factor for disease progression in multiple sclerosis (MS). Because of this, treatments that can reduce the consequences of molecular aging, like senescence, have been proposed as a strategy to address …

Proceedings of the National Academy of Sciences of the United States of America

46 Early

Preliminary Cellular — Research on cellular-level aging mechanisms In Vitro bioRxiv

Naked mole-rats handle cell stress differently: a closer look at their autophagy system

Researchers developed a new tool to watch autophagy (cellular recycling) in real time in naked mole-rat cells and discovered that these long-lived animals respond to stress by forming temporary vacuoles—a protective response that reverses when …

biorxiv (preprint)

30 Early

Preliminary Cellular — Research on cellular-level aging mechanisms Animal Model PubMed

New hydrogel with stem cell vesicles reverses aging damage in bone healing

Researchers created a gel that helps aging bones heal better by reducing inflammation and protecting stem cells from aging damage.

Researchers created a gel containing special vesicles from stem cells that reduces inflammation and cellular aging in aging bone, significantly improving bone and tendon healing in an osteoporosis model. This demonstrates a novel 'senomorphic' approach—directly …

Advanced science (Weinheim, Baden-Wurttemberg, Germany)

42 Early

Preliminary Cellular — Research on cellular-level aging mechanisms Review / Commentary PubMed

How aging cells slow wound healing in diabetes—and new treatments that might help

Clearing out old damaged cells might help diabetic wounds heal better and reduce serious complications.

This review examines how senescent (aged) cells impair diabetic wound healing by triggering chronic inflammation. The authors discuss emerging drugs called senolytics that clear these harmful cells, suggesting a new therapeutic approach to treating stubborn …

Journal of biochemistry

33 Early

Preliminary Biomarkers — Aging clocks and measurement tools Other PubMed

Changes in Cellular Senescence Biomarkers Across Individuals at Different Stages of HIV Infection Before and After a Year on Antiretroviral Therapy.

BACKGROUND: People with HIV (PWH) experience chronic inflammation and more age-related comorbidities despite antiretroviral therapy (ART). Classical senescence biomarkers (e.g., SA-βGal, p16INK4a, γH2AX and Bcl-2) and senescence-associated secretory phenotype (SASP) factors such as IL-6 reflect …

The Journal of infectious diseases

38 Early

Preliminary Pharmacological — Drugs and compounds that may slow or reverse aging. Rapamycin, metformin, NAD+ … Other PubMed

Integrative Approaches to Treating Cellular Senescence in Kidney Disease.

Cellular senescence in the kidney plays a crucial role in the progression of acute kidney injury and chronic kidney disease. Therapeutic approaches targeting senescent cells, such as small molecule senolytic and senomorphic drugs, display efficacy …

Advanced science (Weinheim, Baden-Wurttemberg, Germany)

46 Early

Preliminary Pharmacological — Drugs and compounds that may slow or reverse aging. Rapamycin, metformin, NAD+ … In Vitro PubMed

Natural compound DMB reduces cellular aging by activating DNA repair protein FEN1

Researchers found that demethyleneberberine (DMB), a natural compound from tree bark, can reverse signs of cellular aging in human fibroblasts and extend lifespan in C. elegans by activating a DNA repair enzyme called FEN1. While …

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie

36 Early

Preliminary Cellular — Research on cellular-level aging mechanisms Animal Model PubMed

Can senolytic drugs restore fertility in female mice with fatty liver disease?

Researchers treated female mice with fatty liver disease (MASLD) using senolytic drugs—compounds that eliminate senescent (aged) cells—and found pregnancy rates improved, particularly through reduced aging and inflammation in the ovaries. However, the treatment had limited …

Biology of reproduction

39 Early

Preliminary Clinical Translation — Clinical trials, drug repurposing, regulatory pathways, and geroprotectors in humans Other medRxiv

Testing Three Anti-Aging Drugs in Older Adults: A Clinical Trial Protocol

This is a protocol paper describing an upcoming clinical trial that will test whether three drugs (metformin, fisetin, and spermidine) can reduce senescent cells and reverse aging hallmarks in healthy adults over 70 within three …

medrxiv (preprint)

30 Early

Preliminary Cellular — Research on cellular-level aging mechanisms Review / Commentary PubMed

How IGF-1 Triggers Cellular Aging: A New Model for Targeted Rejuvenation

This review proposes that insulin-like growth factor 1 (IGF-1) acts like a 'switch' for cellular aging—brief exposure helps cells, but chronic exposure drives inflammation and senescence. The authors argue IGF-1 regulation should be a key …

Cytokine

31 Early

Preliminary Cellular — Research on cellular-level aging mechanisms Animal Model PubMed

Can senolytic drugs prevent bone loss in aging and gum disease?

Researchers tested whether dasatinib and quercetin—drugs that eliminate senescent (aging) cells—could prevent bone loss in the jaw. The treatment worked in naturally aged mice but failed in a gum disease model, suggesting senolytic benefits may …

Journal of periodontology

42 Early

Preliminary Clinical Translation — Clinical trials, drug repurposing, regulatory pathways, and geroprotectors in humans Review / Commentary PubMed

How aging immune systems damage lungs—and what treatments might help

If your immune system ages slower, your lungs might stay healthier longer—but we need better treatments to prove it works.

This review examines how immunosenescence (age-related immune decline) drives lung diseases like COPD, fibrosis, and cancer, and surveys emerging treatments including senolytics, stem cell therapy, and lifestyle interventions. While it synthesizes current knowledge well, it's …

BMC medicine

36 Early

Preliminary Clinical Translation — Clinical trials, drug repurposing, regulatory pathways, and geroprotectors in humans Review / Commentary PubMed

Can We Restore Aging Immune Systems to Make Cancer Drugs Work Better?

As people age, their immune systems weaken, which may reduce how well cancer immunotherapy works—especially in patients over 75. Researchers are testing mRNA-based approaches and senolytics (drugs that clear damaged cells) to reverse this immune …

Cancer discovery

36 Early

Preliminary Genetics & Genomics — Gene therapy, CRISPR, epigenetic clocks, and genomic determinants of aging Other PubMed

Interweaving microglial senescence and gut microbiome dynamics in Alzheimer's disease - Mechanisms and therapeutic frontiers.

Alzheimer's disease (AD), a prevalent neurodegenerative disorder characterized by cognitive impairment and neuronal degeneration, is increasingly recognized as being driven not only by the traditional amyloid-beta and tau pathologies but also by persistent neuroinflammation and …

Molecular and cellular neurosciences

46 Early

Preliminary Clinical Translation — Clinical trials, drug repurposing, regulatory pathways, and geroprotectors in humans Other PubMed

Immunosenescence in Human Disease: Mechanistic Insights and Therapeutic Opportunities.

Immunosenescence, an age-associated decline in immune function, is increasingly recognized as a central determinant of health and disease in older adults. Characterized by thymic involution, loss of naïve T cells, contraction of T cell receptor …

Biomolecules & therapeutics

38 Early

Preliminary Pharmacological — Drugs and compounds that may slow or reverse aging. Rapamycin, metformin, NAD+ … Other PubMed

Dual binding modes of Quercetin to BSA: Insights from spectroscopy and molecular simulations in amyloid suppression.

The rising incidence of neurodegenerative disorders linked to protein fibrillation in aging populations highlights the need for efficient, low-toxicity fibrillation inhibitors. Quercetin, a natural flavonoid, shows potential in both suppressing fibrillation and disaggregating mature fibrils. …

Spectrochimica acta. Part A, Molecular and biomolecular spectroscopy

38 Early

Preliminary Cellular — Research on cellular-level aging mechanisms Other PubMed

Mitochondrial Quantity-Quality Imbalance in Cellular Senescence: Practical Readouts and Minimal Assay Bundles.

Cellular senescence is an irreversible program of cell-cycle arrest that accumulates with age, contributing to chronic inflammation and various age-related diseases. A key feature of senescence paradigms is mitochondrial dysfunction, which involves not just a …

BMB reports

38 Early

Preliminary Cellular — Research on cellular-level aging mechanisms Animal Model PubMed

A drug combo slows spine disc aging in mice with genetic predisposition

A drug combination cleared aging cells in mice's spines, slowing damage. It hasn't been tested in people with back pain yet.

Researchers found that two drugs given together—dasatinib and quercetin—slowed age-related disc degeneration in genetically susceptible mice by clearing senescent (aged) cells. The treatment worked in mice's discs but hasn't been tested in humans yet, and …

Bone research

46 Early